Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.

London Health Sciences Centre Research Institute

Status and phase: Not yet enrolling; Phase 2

Conditions: Hemodialysis

Treatments: Drug: AV-001 or Placebo Injection

Study type: Interventional

Funder types: Other

Identifiers

NCT07234890

15976

Details and patient eligibility

About

Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy.

This research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation.

If successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.

Full description

Hemodialysis provides life-sustaining treatment for many chronic kidney disease patients around the world. Moderate to severe cognitive impairment is very common in HD patients with up to 70% being affected who are ≥ 55 years of age and ~ 10% in those between 21-39 years of age. Significant cognitive impairment is evident within 6 months of starting HD.

This study is a phase 2 exploratory study in patients receiving hemodialysis treatments. Investigators will recruit 60 patients from the renal program at the London Health Sciences Centre.

Study participants will receive AV-001 (low or high dose) or placebo 60 minutes prior to HD initiation at 3 HD treatment sessions within 1 week (Monday, Wednesday and Friday)

Study participants will also undergo:

• Vital sign collection (blood pressure and heart rate)
• Blood collection
• Cognitive assessments
• Vascular ultrasound
• MRI

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ability to provide informed consent
• Male and non-pregnant female patients (>18 years old)
• HD for ≥ 3 months
• Thrice weekly HD schedule

Exclusion criteria

• HD <90 days
• Contraindication to MRI
• Established severe cognitive impairment (Montreal Cognitive Assessment test (MoCA) <18 or formal diagnosis of dementia)
• Previous clinical stroke
• Pregnancy, breastfeeding, or intending pregnancy
• Intradialytic hypotension event (defined as: drop in SBP ≥40mmHg + symptoms + intervention) in previous month as evidenced by HD record

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 3 patient groups

Group 1 Placebo

Experimental group

Description:

Participants randomized into one group 1placebo. Placebo will be administered 60 minutes prior to hemodialysis initiation, 3 x over a one-week treatment period.

Treatment:

Drug: AV-001 or Placebo Injection

Group 2: AV-001 low dose (12.5μg/kg)

Experimental group

Description:

Participants randomized into group 2 will receive AV-001 low dose. AV-001 low dose will be administered 60 minutes prior to hemodialysis initiation, 3 x over a one-week treatment period.

Treatment:

Drug: AV-001 or Placebo Injection

Group 3: AV-001 High Dose (25μg/kg)

Experimental group

Description:

Participants randomized into group 3 will receive AV-001 high dose. AV-001 high dose will be administered 60 minutes prior to hemodialysis initiation, 3 x over a one-week treatment period.

Treatment:

Drug: AV-001 or Placebo Injection